Invention Grant
US08119117B2 Adenoviral expression vector comprising a CD40L fusion protein adapted to elicit cellular immunity
有权
包含适于引发细胞免疫的CD40L融合蛋白的腺病毒表达载体
- Patent Title: Adenoviral expression vector comprising a CD40L fusion protein adapted to elicit cellular immunity
- Patent Title (中): 包含适于引发细胞免疫的CD40L融合蛋白的腺病毒表达载体
-
Application No.: US10534605Application Date: 2003-11-12
-
Publication No.: US08119117B2Publication Date: 2012-02-21
- Inventor: Albert B. Deisseroth , Lixin Zhang
- Applicant: Albert B. Deisseroth , Lixin Zhang
- Applicant Address: US VA Manassas
- Assignee: VAXum, LLC
- Current Assignee: VAXum, LLC
- Current Assignee Address: US VA Manassas
- Agent Jacob Frank; Glenn Snyder
- International Application: PCT/US03/36237 WO 20031112
- International Announcement: WO2004/044176 WO 20040527
- Main IPC: A61K48/00
- IPC: A61K48/00 ; C12N15/00

Abstract:
Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which enocodes the E6 or E7 protein of HPV. The immunity generated is long term.
Public/Granted literature
- US20070269409A1 Adenoviral Vector Vaccine Public/Granted day:2007-11-22
Information query